<DOC>
	<DOCNO>NCT00324623</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide fludarabine , may use prepare body treatment , cellular adoptive immunotherapy . Biological therapy , cellular adoptive immunotherapy , may stimulate immune system different way stop tumor cell grow . Vaccines may help body build effective immune response kill tumor cell . Giving cyclophosphamide together fludarabine follow biological therapy may effective treatment metastatic melanoma . PURPOSE : This phase I trial study side effect give cyclophosphamide together fludarabine follow cellular adoptive immunotherapy , vaccine therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Cyclophosphamide Fludarabine Followed Cellular Adoptive Immunotherapy Vaccine Therapy Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine magnitude duration expansion antigen-specific T-cells present post-vaccination peripheral blood mononuclear cell reinfused immunosuppression patient metastatic melanoma . - Characterize T-cell subset ( phenotype , function , T-cell receptor repertoire ) patient . - Determine tumor response patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This open-label dose-finding study . Patients undergo leukapheresis collect whole peripheral blood mononuclear cell ( PBMC ) . Patients assign 1 3 treatment group . - Group 1 ( close accrual 5/8/2007 ) : Patients receive cyclophosphamide IV day -7 -6 fludarabine IV day -5 -3 . Patients undergo autologous PBMC infusion day 0 . Patients also receive vaccination comprise Melan-A vaccine emulsify incomplete Freund 's adjuvant ( IFA ) subcutaneously ( SC ) every 3 week begin day 0 . - Group 2 ( close accrual 8/15/2007 ) : Patients receive cyclophosphamide IV high dose group 1 day -7 -6 fludarabine IV day -5 -3 . Patients also receive autologous PBMC infusion Melan-A vaccine emulsify IFA group 1 . - Group 3 : Patients receive cyclophosphamide IV 30 mg/kg day -7 -6 . Patients also receive fludarabine 30 mg/m2 IV day -5 -3 , autologous PBMC infusion day 0 , Melan-A vaccine emulsify IFA IMP321 . The first 3 patient receive 25 microgram IMP321 , absence severe 3 4 toxicity , dose escalate IMP321 250 microgram . PROJECTED ACCRUAL : A total 9 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma Progressive disease receive prior MelanA peptide vaccine immunotherapy protocol Ludwig Institute AND achieve detectable immune response ( increase specific CD8^+ TET^+ MelanA ) Tumor must express MART1/MelanA antigen HLAA2 positive Not eligible protocol due progressive disease OR maximum number vaccine injection stable disease attain PATIENT CHARACTERISTICS : Performance status 02 Whole blood count normal Pulmonary status normal Transaminases &lt; 1.5 time upper limit normal ( ULN ) Gammaglutamyltransferase &lt; 1.5 time ULN Bilirubin normal Creatinine clearance &gt; 70 mL/min No major uncontrolled heart disease No arterial hypertension PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior chemotherapy , biologic therapy , radiotherapy , and/or surgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>